Page 383 - ONLINE PROCEEDING BOOK WSAVA 2017
P. 383

WSVA7-0575
MEDICAL ONCOLOGY
CANINE LYMPHOMA
A.T. Kristensen1
1Oncology and Veterinary Clinical Pathology, Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Dyrlægevej 16, 1870 Frederiksberg C, Denmark
Introduction
Canine lymphoma is one of the most investigated cancers in veterinary oncology. Multiple studies evaluating prognostic factors, biomarkers, a multitude
of single and multi-agent chemotherapy protocols, multimodality treatment approaches, evaluation of minimal residual disease, novel therapeutic approaches as well as novel information on advanced imaging procedures in the diagnosis of canine lymphoma patients have been reported. In addition, studies comparing maintenance free chemotherapy (discontinuous)
to continuous protocols including maintenance chemotherapy have been published.
Standard of Care?
Despite these efforts Standard of Care (SOC) for diagnosis, staging, treatment and follow up management has not been de ned for canine lymphoma. This is
most likely because many patients are not consistently diagnosed, staged or classi ed according to currently possible classi cation schemes. Furthermore the majority of studies are retrospective in nature encompassing a multitude of lymphoma types, anatomic locations and inconsistent diagnostic and staging criteria prior to therapy. Many patients only have a cytological diagnosis and some are not staged prior to therapy as cost issues may favor spending the client’s resources on treatment rather than diagnostics. In addition, the current treatment approach is a “one size  ts all” approach which is hugely discordant with the diagnostic and treatment approaches in human oncology.
European Canine Lymphoma Network
In 2016, The European Canine Lymphoma Network (ECLN) (Marconata et al, VCO, 2016), reported a systematic review of the past 15 years of canine lymphoma study publications representing the latest collected information on canine lymphoma. This commendable effort was undertaken to learn from previous studies and to potentially supply future recommendations for the diagnosis, management and follow up of canine lymphoma. The authors evaluated 63 treatment studies of which only 8 were randomized controlled trials and of these only 2 concerned a single lymphoma diagnosis. One of the expected conclusions
of the systematic review was that the majority of studies do not have the consistency required to make valid conclusions and recommendations. Therefore
the overall conclusion was a set of recommendations to be followed in future prospective studies as a minimum, but preferentially also to be followed in all canine lymphoma patients to improve the possibility to compare results across studies and patients. A short version of the recommendations is provided below but no recommendation was made regarding treatment regimen. Please refer to Marconato et al, VCO 2016 for the full review and more detailed information.
ECLN recommendation regarding:
Diagnosis: As a minimum WHO classi cation of lymphoma type as to B or T immune-phenotype should be performed ( ow cytometry, immunohistochemistry (IHC)). For histopathology excisional lymph node biopsies should be preferred.
Clinical staging prior to initiation of therapy: A minimum database (MDB) consisting of a complete hemogram including blood smear evaluation, biochemistry, and urinalysis, thoracic and abdominal imaging by either X-Ray, ultrasound, CT or MRI as appropriate. Hepatic and splenic  ne needle aspirates (FNAsp) for cytology as well as bone marrow aspirates and core biopsies.
Response evaluation criteria: restaging including if possible evaluation for minimal residual disease (MRD): For discontinuous protocols: 2–4 weeks following administration of  nal chemotherapy treatment; for continuous protocols: 4–6 months after initiation of therapy:
MDB with a complete hemogram incl. blood smear evaluation, biochemistry, and urinalysis, thoracic and abdominal imaging by either X-Ray, ultrasound, CT or MRI as appropriate. Hepatic and splenic FNAsp for cytology as well as bone marrow aspirates and core biopsies and MRD determination.
Follow-up: Monthly for one year and bimonthly thereafter: physical examination, lymph node FNAsp. If suspicion of relapse con rmation by cytology or histopathology.
On the horizon
The future diagnosis, management and prognostication of canine lymphoma likely will include biomarkers, scoring systems such as the modi ed Glasgow prognostication score (mGPS), molecular diagnostic techniques, molecular imaging (PET-CT, PET-MRI and potentially also HyperPET) as well as species speci c immune therapeutic approaches.
An Urban Experience
383


































































































   381   382   383   384   385